In a busy diabetes clinic, it is always easy for the diabetologist to equate nephropathy and diabetes to “diabetic nephropathy”. Certain clinical clues should arouse suspicion of non-diabetic renal disease as this may have important implications in patient management. We report a case of multiple myeloma in a patient with diabetes presenting as “diabetic nephropathy”.
IssaZAZantoutMSAzarST. Multiple myeloma and diabetes. ISRN Endocrinol2011; 2011: 815013.
2.
ChouYSYangCFChenHS. Pre-existing diabetes mellitus in patients with multiple myeloma. Eur J Haematol2012; 89: 320-327.
3.
O’NeillWMJrWallinJDand WalkerPD. Hematuria and red cell casts in typical diabetic nephropathy. Am J Med1983; 74: 389.
4.
ParvingHHGallMASkøttP. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int1992; 41: 758.
5.
BladéJFernández-LlamaPBoschF. Diabetes and Nephropathy: Not always synonymous!Arch Intern Med1998; 158: 1889-1893.
6.
GaedePLund-AndersenHParvingHH. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008; 358: 580-591.
7.
BorrelloIFergusonAHuffCA. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma, efficacy and neurotoxicity. ASH Annual Meeting abstracts 108, abstract no. 3528. Blood2006.
8.
BadrosAGoloubevaODalalJS. Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature. Cancer2007; 110: 1042-1049.
9.
PalPK. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol1999; 39: 323-330.
10.
IqbalNZayedMand BodenG. Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes. Diabetes Care2000; 23: 1172-1176.
